Oric Pharmaceuticals Inc
ORIC10.780USD
-0.080-0.74%
Fechamento 09/12, 16:00（ET）Cotações atrasadas em 15 min
929.10MValor de mercado
PerdaP/L TTM
Mais detalhes de Oric Pharmaceuticals Inc Empresa
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.
Informações da empresa
Código da empresaORIC
Nome da EmpresaOric Pharmaceuticals Inc
Data de listagemApr 24, 2020
CEODr. Jacob M. Chacko, M.D.
Número de funcionários115
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 24
Endereço240 E. Grand Ave
CidadeSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94080
Telefone16503885600
Sitehttps://oricpharma.com/
Código da empresaORIC
Data de listagemApr 24, 2020
CEODr. Jacob M. Chacko, M.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jacob M. Chacko, M.D.
Dr. Jacob M. Chacko, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
778.65K
+1.01%
Dr. Richard A. (Rich) Heyman, Ph.D.
Dr. Richard A. (Rich) Heyman, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
228.77K
--
Dr. Kevin Brodbeck, Ph.D.
Dr. Kevin Brodbeck, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Mr. Dominic G. Piscitelli, CPA
Mr. Dominic G. Piscitelli, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Pratik S. Multani, M.D.
Dr. Pratik S. Multani, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Mardi C. Dier
Ms. Mardi C. Dier
Independent Director
Independent Director
--
--
Mr. Steven L. (Steve) Hoerter
Mr. Steven L. (Steve) Hoerter
Independent Director
Independent Director
--
--
Dr. Lori A. Kunkel, M.D.
Dr. Lori A. Kunkel, M.D.
Independent Director
Independent Director
--
--
Dr. Angie J. You, Ph.D.
Dr. Angie J. You, Ph.D.
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jacob M. Chacko, M.D.
Dr. Jacob M. Chacko, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
778.65K
+1.01%
Dr. Richard A. (Rich) Heyman, Ph.D.
Dr. Richard A. (Rich) Heyman, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
228.77K
--
Dr. Kevin Brodbeck, Ph.D.
Dr. Kevin Brodbeck, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Mr. Dominic G. Piscitelli, CPA
Mr. Dominic G. Piscitelli, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Pratik S. Multani, M.D.
Dr. Pratik S. Multani, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Mardi C. Dier
Ms. Mardi C. Dier
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: dom, 31 de ago
Atualizado em: dom, 31 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Nextech Invest, Ltd.
7.37%
EcoR1 Capital, LLC
6.93%
VR Adviser, LLC
6.79%
Viking Global Investors LP
6.77%
Pfizer Inc
5.54%
Outro
66.60%
Investidores
Investidores
Proporção
Nextech Invest, Ltd.
7.37%
EcoR1 Capital, LLC
6.93%
VR Adviser, LLC
6.79%
Viking Global Investors LP
6.77%
Pfizer Inc
5.54%
Outro
66.60%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
28.79%
Investment Advisor
26.57%
Venture Capital
22.65%
Hedge Fund
14.71%
Corporation
5.54%
Private Equity
2.02%
Sovereign Wealth Fund
1.98%
Individual Investor
1.43%
Research Firm
1.21%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
288
93.19M
110.15%
+12.20M
2025Q1
294
83.96M
99.59%
+456.78K
2024Q4
284
80.39M
113.18%
-3.73M
2024Q3
272
78.70M
112.04%
-2.29M
2024Q2
265
76.25M
113.03%
-1.57M
2024Q1
276
71.21M
105.62%
-1.02M
2023Q4
259
57.91M
108.09%
+1.21M
2023Q3
260
55.20M
103.62%
-1.09M
2023Q2
255
52.76M
117.11%
+8.95M
2023Q1
257
40.28M
89.44%
-3.51M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Nextech Invest, Ltd.
5.29M
6.2%
--
--
Mar 31, 2025
EcoR1 Capital, LLC
3.42M
4.01%
--
--
Mar 31, 2025
VR Adviser, LLC
6.60M
7.74%
+3.41M
+107.28%
Apr 08, 2025
Viking Global Investors LP
6.57M
7.71%
+2.14M
+48.33%
Mar 31, 2025
Pfizer Inc
5.38M
6.31%
--
--
Mar 31, 2025
SR One Capital Management, LP
4.62M
5.42%
+4.62M
--
May 29, 2025
New Enterprise Associates (NEA)
2.20M
2.58%
+629.46K
+40.19%
Mar 31, 2025
Alkeon Capital Management LLC
3.34M
3.92%
+86.63K
+2.66%
Mar 31, 2025
The Column Group LP
3.54M
4.15%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.40M
5.16%
+59.93K
+1.38%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de set
Atualizado em: sáb, 6 de set
Nome
Proporção
iShares Genomics Immunology and Healthcare ETF
0.93%
SPDR S&P Biotech ETF
0.11%
iShares Micro-Cap ETF
0.1%
Direxion Daily S&P Biotech Bull 3X Shares
0.06%
iShares Biotechnology ETF
0.05%
Fidelity Enhanced Small Cap ETF
0.05%
Avantis US Small Cap Equity ETF
0.05%
Vanguard US Momentum Factor ETF
0.03%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Ver Mais
iShares Genomics Immunology and Healthcare ETF
Proporção0.93%
SPDR S&P Biotech ETF
Proporção0.11%
iShares Micro-Cap ETF
Proporção0.1%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.06%
iShares Biotechnology ETF
Proporção0.05%
Fidelity Enhanced Small Cap ETF
Proporção0.05%
Avantis US Small Cap Equity ETF
Proporção0.05%
Vanguard US Momentum Factor ETF
Proporção0.03%
ProShares Hedge Replication ETF
Proporção0.02%
iShares Russell 2000 Value ETF
Proporção0.02%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
